TAKEDA PHARMACEUTICAL CO LTD News

6-K: Amendment Extraordinary Report

Dec 18 06:04 ET

6-K: The 148th Interim Period Business Report

Dec 2 06:06 ET

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Sep 26 06:13 ET

6-K: Takeda Completed Issuance of New Shares and Disposal of Treasury Shares under the Long-Term Incentive Plan for Company Group Employees Outside of Japan with Partial Forfeiture of Rights Granted to Allottees

Jul 9 06:10 ET

6-K: Closure of Notes Sale Pursuant

Jul 5 11:32 ET

6-K: Results of the Exercise of Voting Rights of the 148th Ordinary General Meeting of Shareholders

Jul 2 06:24 ET

6-K: Takeda Announces New Assignments of Directors

Jun 26 06:03 ET

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Jun 17 06:50 ET

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Jun 11 06:27 ET

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Jun 10 06:13 ET

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Jun 7 06:07 ET

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Jun 3 06:50 ET

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Jun 3 06:30 ET

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

May 29 06:32 ET

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

May 9 06:12 ET

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

May 9 06:10 ET

6-K: U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease

Apr 19 06:15 ET

TAKEDA PHARMACEUTICAL CO LTD | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Apr 15 06:33 ET

TAKEDA PHARMACEUTICAL CO LTD | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Mar 27 06:38 ET

TAKEDA PHARMACEUTICAL CO LTD | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Feb 9 06:09 ET